Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Nurix Therapeutics, Inc. Common stock

NRIX

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Last trade $14.25
Day change -$0.485 (-3.29%)
Day range $14.12 – $15.26
Volume 1,058,804
Market cap $1.61B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.61B
Price / earnings
5.46×
Price / book
1.66×
Price / sales
2.29×
EV / sales
1.27×
EV / EBITDA
2.98×

Profitability

Earnings per share
$2.70
Return on assets
24.67%
Return on equity
30.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.44×
Quick ratio
8.44×
Cash ratio
5.51×

Cash flow

Price / cash flow
4.24×
Price / free cash flow
4.35×
Free cash flow
$369.81M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NRIX, quarterly periods
Line itemQ3 FY2026 Aug 31, 2026Q2 FY2026 May 31, 2026Q1 FY2026 Feb 28, 2026Q4 FY2025 Nov 30, 2025Q3 FY2025 Aug 31, 2025Q2 FY2025 May 31, 2025Q1 FY2025 Feb 28, 2025Q4 FY2024 Nov 30, 2024
Revenue$673.06M$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$673.06M$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M
Selling, general and administrative$34.35M$15.59M$14.61M$13.65M$13.16M$14.28M$11.65M$10.72M
Research and development$79.26M$87.65M$84.14M$83.02M$86.12M$78.1M$69.66M$67.22M
Total operating expenses$113.61M$103.25M$98.75M$96.67M$99.28M$92.38M$81.32M$77.94M
Operating income$559.45M-$94.2M-$92.5M-$83.1M-$91.39M-$48.32M-$62.86M-$64.66M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$563.41M-$89.81M-$87.17M-$78.22M-$86.42M-$42.7M-$56.35M-$58.54M
Income taxes$13.61M-$271K$0$0$0$760K$0$8K
Net income$549.81M-$89.54M-$87.17M-$78.22M-$86.42M-$43.46M-$56.35M-$58.55M
Net income attributable to common shareholders$549.81M-$89.54M-$87.17M-$78.22M-$86.42M-$43.46M-$56.35M-$58.55M
EBITDA$561.59M-$91.95M-$90.3M-$80.98M-$89.36M-$46.08M-$60.51M-$62.11M
Basic earnings per share$4.93-$0.81-$0.79-$0.82-$1.03-$0.52-$0.67-$0.75
Diluted earnings per share$4.73-$0.81-$0.79-$0.82-$1.03-$0.52-$0.67-$0.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances

Swiss pharma giant Roche Holding AG reported first-nine-month 2026 sales of CHF 46.5 billion, up 6% at constant exchange rates, driven by 7% growth in its Pharmaceuticals division. Five key drugs generated CHF 16.8 billion in sales, up 12% at CER, offsetting declines in legacy products due to loss of exclusivity. The company reaffirmed mid-single-digit sales growth guidance for 2026 and expects high-single-digit EPS growth. Roche's pipeline includes promising candidates in oncology, immunology, and obesity treatment, with enicepatide showing encouraging phase II results for type 2 diabetes and weight management.

Zacks Investment Research

Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?

Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.

Zacks Investment Research

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.

Zacks Investment Research

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.

Zacks Investment Research

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.46 loss, with a 76% earnings surprise. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical - Biomedical and Genetics industry ranks in the bottom 32% of sectors. Nurix Therapeutics (NRIX) is expected to report results with a projected loss of $0.56 per share but with significant revenue growth of 1665.8% year-over-year.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.